• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C 末端结合蛋白(CtBP)底物竞争性抑制剂的设计、合成及生物学评价

Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).

作者信息

Korwar Sudha, Morris Benjamin L, Parikh Hardik I, Coover Robert A, Doughty Tyler W, Love Ian M, Hilbert Brendan J, Royer William E, Kellogg Glen E, Grossman Steven R, Ellis Keith C

机构信息

Department of Medicinal Chemistry, School of Pharmacy, The Institute for Structural Biology, Drug Discovery, and Development, and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States.

Division of Hematology, Oncology, & Palliative Care, Department of Human and Molecular Genetics, and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States.

出版信息

Bioorg Med Chem. 2016 Jun 15;24(12):2707-15. doi: 10.1016/j.bmc.2016.04.037. Epub 2016 Apr 20.

DOI:10.1016/j.bmc.2016.04.037
PMID:27156192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4993153/
Abstract

C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD(+) as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50=0.24μM). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50=0.18μM) and 3-chloro- (IC50=0.17μM) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer.

摘要

C末端结合蛋白(CtBP)是一种转录共调节因子,可下调许多肿瘤抑制基因的表达。利用CtBP与底物4-甲基硫代-2-氧代丁酸(MTOB)和NAD(+)的晶体结构作为指导,我们设计、合成并测试了一系列CtBP的小分子抑制剂。从我们的第一轮化合物中,我们鉴定出2-(羟基亚氨基)-3-苯基丙酸为一种有效的CtBP抑制剂(IC50 = 0.24μM)。对该化合物的构效关系研究进一步确定4-氯-(IC50 = 0.18μM)和3-氯-(IC50 = 0.17μM)类似物为另外的有效CtBP抑制剂。在短期细胞生长/活力测定中对羟基亚胺类似物的评估表明,4-氯-和3-氯-类似物分别比MTOB对照强2倍和4倍。使用CtBP特异性转录读数的功能性细胞测定表明,4-氯-和3-氯-羟基亚胺类似物能够阻断CtBP转录抑制活性。该数据表明,CtBP脱氢酶活性的底物竞争性抑制是重新激活肿瘤抑制基因表达作为癌症治疗策略的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/7ff69e266c12/nihms-784353-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/d72e4f9c7bba/nihms-784353-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/6f11251f4155/nihms-784353-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/af3572273958/nihms-784353-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/fc89e00242d6/nihms-784353-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/c160244ae4a8/nihms-784353-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/c8a99a020f16/nihms-784353-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/e8f974b121df/nihms-784353-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/beda10b5ddcb/nihms-784353-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/b307cbe905db/nihms-784353-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/7ff69e266c12/nihms-784353-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/d72e4f9c7bba/nihms-784353-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/6f11251f4155/nihms-784353-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/af3572273958/nihms-784353-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/fc89e00242d6/nihms-784353-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/c160244ae4a8/nihms-784353-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/c8a99a020f16/nihms-784353-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/e8f974b121df/nihms-784353-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/beda10b5ddcb/nihms-784353-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/b307cbe905db/nihms-784353-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/179d/4993153/7ff69e266c12/nihms-784353-f0011.jpg

相似文献

1
Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).C 末端结合蛋白(CtBP)底物竞争性抑制剂的设计、合成及生物学评价
Bioorg Med Chem. 2016 Jun 15;24(12):2707-15. doi: 10.1016/j.bmc.2016.04.037. Epub 2016 Apr 20.
2
Structure-guided design of a high affinity inhibitor to human CtBP.针对人CtBP的高亲和力抑制剂的结构导向设计。
ACS Chem Biol. 2015 Apr 17;10(4):1118-27. doi: 10.1021/cb500820b. Epub 2015 Jan 30.
3
Therapeutic targeting of C-terminal binding protein in human cancer.靶向人癌症中 C 端结合蛋白的治疗。
Cell Cycle. 2010 Sep 15;9(18):3740-50. doi: 10.4161/cc.9.18.12936. Epub 2010 Sep 8.
4
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.人源 CtBP 与底物 MTOB 复合物的晶体结构揭示了对抑制剂设计有用的活性位点特征。
FEBS Lett. 2014 May 2;588(9):1743-8. doi: 10.1016/j.febslet.2014.03.026. Epub 2014 Mar 19.
5
Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.活性位点色氨酸是抗肿瘤 C 端结合蛋白抑制剂的作用靶点,介导抑制剂破坏 CtBP 寡聚化和转录共调节活性。
Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
6
CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors.CtBP——一种新兴的致癌基因和新型小分子药物靶点:对其致癌作用的理解及治疗性抑制剂鉴定的进展
Cancer Biol Ther. 2017 Jun 3;18(6):379-391. doi: 10.1080/15384047.2017.1323586. Epub 2017 May 22.
7
CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4.CtBP 通过调节 SIRT4 维持癌细胞生长和代谢平衡。
Cell Death Dis. 2015 Jan 29;6(1):e1620. doi: 10.1038/cddis.2014.587.
8
CPP-E1A fusion peptides inhibit CtBP-mediated transcriptional repression.CPP-E1A 融合肽抑制 CtBP 介导的转录抑制。
Mol Oncol. 2018 Aug;12(8):1358-1373. doi: 10.1002/1878-0261.12330. Epub 2018 Jun 23.
9
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells.鉴定并描述一种新型靶向黑色素瘤细胞 CtBP1/BARS 的有效抑制剂。
J Exp Clin Cancer Res. 2024 May 6;43(1):137. doi: 10.1186/s13046-024-03044-5.
10
Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression.小分子NSC95397可抑制CtBP1与蛋白伴侣的相互作用以及CtBP1介导的转录抑制。
J Biomol Screen. 2015 Jun;20(5):663-72. doi: 10.1177/1087057114561400. Epub 2014 Dec 4.

引用本文的文献

1
The specificity of CTBP dehydrogenase inhibitors MTOB and 4-Cl-HIPP.CTBP脱氢酶抑制剂MTOB和4-氯-HIPP的特异性
MicroPubl Biol. 2025 Feb 3;2025. doi: 10.17912/micropub.biology.001415. eCollection 2025.
2
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.一种用于网络生物信息学的新方法鉴定出了黏液性卵巢癌的新药物靶点。
NAR Genom Bioinform. 2024 Aug 24;6(3):lqae096. doi: 10.1093/nargab/lqae096. eCollection 2024 Sep.
3
C-Terminal Binding Protein: Regulator between Viral Infection and Tumorigenesis.

本文引用的文献

1
A cyclic peptide inhibitor of C-terminal binding protein dimerization links metabolism with mitotic fidelity in breast cancer cells.一种C末端结合蛋白二聚化的环肽抑制剂将乳腺癌细胞中的代谢与有丝分裂保真度联系起来。
Chem Sci. 2013 Aug 1;4(8):3046-3057. doi: 10.1039/c3sc50481f.
2
Structure-guided design of a high affinity inhibitor to human CtBP.针对人CtBP的高亲和力抑制剂的结构导向设计。
ACS Chem Biol. 2015 Apr 17;10(4):1118-27. doi: 10.1021/cb500820b. Epub 2015 Jan 30.
3
Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression.
C 端结合蛋白:病毒感染与肿瘤发生之间的调节剂。
Viruses. 2024 Jun 19;16(6):988. doi: 10.3390/v16060988.
4
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells.鉴定并描述一种新型靶向黑色素瘤细胞 CtBP1/BARS 的有效抑制剂。
J Exp Clin Cancer Res. 2024 May 6;43(1):137. doi: 10.1186/s13046-024-03044-5.
5
Merging cultures and disciplines to create a drug discovery ecosystem at Virginia commonwealth university: Medicinal chemistry, structural biology, molecular and behavioral pharmacology and computational chemistry.弗吉尼亚联邦大学融合文化与学科,创建药物发现生态系统:药用化学、结构生物学、分子和行为药理学以及计算化学。
SLAS Discov. 2023 Sep;28(6):255-269. doi: 10.1016/j.slasd.2023.02.006. Epub 2023 Feb 28.
6
Elevation of hsa-miR-7-5p level mediated by CtBP1-p300-AP1 complex targets ATXN1 to trigger NF-κB-dependent inflammation response.由CtBP1-p300-AP1复合物介导的hsa-miR-7-5p水平升高靶向共济失调蛋白1(ATXN1),以触发核因子κB(NF-κB)依赖性炎症反应。
J Mol Med (Berl). 2023 Mar;101(3):223-235. doi: 10.1007/s00109-022-02274-4. Epub 2023 Jan 11.
7
Transcriptomics and Metabolomics Integration Reveals Redox-Dependent Metabolic Rewiring in Breast Cancer Cells.转录组学与代谢组学整合揭示乳腺癌细胞中氧化还原依赖性代谢重编程
Cancers (Basel). 2021 Oct 9;13(20):5058. doi: 10.3390/cancers13205058.
8
The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases.CtBPs 在不同疾病发病机制中的反式抑制和反式激活作用。
J Mol Med (Berl). 2021 Oct;99(10):1335-1347. doi: 10.1007/s00109-021-02107-w. Epub 2021 Jul 1.
9
Presence of Bromotyrosine Alkaloids in Marine Sponges Is Independent of Metabolomic and Microbiome Architectures.海洋海绵中溴酪氨酸生物碱的存在与代谢组学和微生物群落结构无关。
mSystems. 2021 Mar 16;6(2):e01387-20. doi: 10.1128/mSystems.01387-20.
10
Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes.EB 病毒核抗原 3C(EBNA3C)与代谢感应 C 端结合蛋白(CtBP)抑制剂相互作用,上调宿主基因。
PLoS Pathog. 2021 Mar 15;17(3):e1009419. doi: 10.1371/journal.ppat.1009419. eCollection 2021 Mar.
小分子NSC95397可抑制CtBP1与蛋白伴侣的相互作用以及CtBP1介导的转录抑制。
J Biomol Screen. 2015 Jun;20(5):663-72. doi: 10.1177/1087057114561400. Epub 2014 Dec 4.
4
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.人源 CtBP 与底物 MTOB 复合物的晶体结构揭示了对抑制剂设计有用的活性位点特征。
FEBS Lett. 2014 May 2;588(9):1743-8. doi: 10.1016/j.febslet.2014.03.026. Epub 2014 Mar 19.
5
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.BRCA1 的表达在散发性卵巢癌细胞中被 C 末端结合蛋白 2 的过表达表观遗传抑制。
Neoplasia. 2013 Jun;15(6):600-8. doi: 10.1593/neo.121674.
6
Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.基因组范围内 CtBP 与乳腺癌的代谢、基因组稳定性和上皮重编程有关。
Nat Commun. 2013;4:1449. doi: 10.1038/ncomms2438.
7
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.C 末端结合蛋白-2 调控上皮性卵巢癌细胞对组蛋白去乙酰化酶抑制剂的反应。
Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.
8
Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.CtBP1 对乳腺癌中 Brca1 和 E-cadherin 的转录下调作用。
Mol Carcinog. 2012 Jun;51(6):500-7. doi: 10.1002/mc.20813. Epub 2011 Jun 16.
9
Therapeutic targeting of C-terminal binding protein in human cancer.靶向人癌症中 C 端结合蛋白的治疗。
Cell Cycle. 2010 Sep 15;9(18):3740-50. doi: 10.4161/cc.9.18.12936. Epub 2010 Sep 8.
10
Hydrophobicity--shake flasks, protein folding and drug discovery.疏水性——摇瓶、蛋白质折叠和药物发现。
Curr Top Med Chem. 2010;10(1):67-83. doi: 10.2174/156802610790232233.